Loading
Latest filing published 20 Aug 2026 for XSpray Pharma AB (publ), €3,486. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Only one filing by Anders Bladh, Ribbskottet is known so far (20 August 2026): an open-market purchase, €3,486, in XSpray Pharma AB (publ). That is too little to draw conclusions. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration